ENDOCRINE PACKET 3

Overview of Hyperthyroidism and Pathophysiology

• Definition of Hyperthyroidism:

  • Characterized by an excess of thyroid hormone—triiodothyronine ($\text{T}_3$) and thyroxine ($\text{T}_4$)—synthesized and secreted into circulation by the thyroid gland.

  • Laboratory hallmarks of primary hyperthyroidism demonstrate suppressed thyroid-stimulating hormone ($\downarrow\text{TSH}$) alongside elevated serum levels of free and total thyroid hormones ($\uparrow\text{T}_3$, $\uparrow\text{T}_4$).

• Etiology of Hyperthyroidism:

  • Graves Disease: Represents the most common underlying cause of hyperthyroidism. It is an autoimmune disorder driven by circulating thyroid-stimulating autoantibodies directed against the thyroid-stimulating hormone ($\text{TSH}$) receptor.

  • Autonomous Thyroid Nodule(s): Toxic adenoma or toxic multinodular goiter functioning independently of pituitary regulatory feedback.

  • Thyroiditis: Inflammatory breakdown of follicular cells resulting in the transient, temporary release of preformed thyroid hormones into circulation.

• Autoimmune Mechanism in Graves Disease:

  • Under normal physiologic conditions, the anterior pituitary secretes $\text{TSH}$, which binds to follicular $\text{TSH}$ receptors on the thyroid cell membrane to stimulate hormone synthesis under tight negative feedback control.

  • In Graves disease, autoantibodies (thyroid-stimulating immunoglobulins) bind directly to and activate the $\text{TSH}$ receptors.

  • This receptor activation bypasses normal negative feedback loops, resulting in continuous, unregulated overproduction and secretion of thyroid hormones ($\text{T}_3$ and $\text{T}_4$).

Clinical Manifestations and Physical Examination

• Hallmark Symptoms ("Think Fast!"):

  • Heat intolerance and increased perspiration due to elevated basal metabolic rate.

  • Neuropsychiatric manifestations including pronounced anxiety, restlessness, and insomnia.

  • Cardiovascular sensations including heart palpitations.

  • Unintentional, rapid weight loss occurring despite a normal or significantly increased appetite.

  • Neuromuscular fine tremors.

  • Gastrointestinal changes characterized by increased stool frequency or looser bowel movements (diarrhea), occasionally accompanied by nausea and vomiting.

  • Menstrual irregularities, including oligomenorrhea or amenorrhea.

• Physical Examination Findings:

  • General: Psychomotor hyperactivity, fidgeting, and visible weight loss.

  • Dermatologic / Integumentary:

  • Warm, moist, diaphoresis-prone skin.

  • Thinning, fine, brittle hair and diffuse hair loss.

  • Pretibial myxedema (infiltrative dermopathy characterized by non-pitting, indurated orange-peel-like lesions over the anterior shins), which is a specific pathognomonic feature of Graves disease.

  • Head, Eyes, Ears, Nose, and Throat (HEENT):

  • Lid Lag: A lag of the upper eyelid behind the globe during downward gaze, observable across all hyperthyroid states due to sympathetic overactivity of the superior palpebral muscle.

  • Exophthalmos (Proptosis): Bulging eyes accompanied by eyelid retraction, scleral show, and eye redness, caused by autoimmune-mediated retro-orbital inflammation and glycosaminoglycan accumulation (specific to Graves disease).

  • Periorbital and Conjunctival Edema (Chemosis): Infiltrative soft-tissue swelling specific to Graves disease.

  • Goiter: Palpable, diffuse, or nodular enlargement of the thyroid gland.

  • Cardiovascular:

  • Resting sinus tachycardia.

  • Irregularly irregular cardiac rhythm indicating atrial fibrillation.

  • Systolic hypertension with widened pulse pressure.

  • Musculoskeletal / Neurologic:

  • Fine postural hand tremor.

  • Proximal muscle weakness (thyrotoxic myopathy), evident when standing from a seated position.

  • Symmetrical hyperreflexia with brisk deep tendon reflexes.

Differential Diagnosis of Hyperthyroxinemia

• Euthyroid Hyperthyroxinemia:

  • Caused by qualitative or quantitative abnormalities in serum thyroid-binding proteins (e.g., elevated thyroxine-binding globulin [TBG], transthyretin abnormalities, or familial dysalbuminemic hyperthyroxinemia).

  • Leads to an elevation in total serum $\text{T}_4$ concentrations while biologically active free $\text{T}_4$, free $\text{T}_3$, and serum $\text{TSH}$ remain within normal reference ranges.

• Glucocorticoid Therapy:

  • High-dose exogenous glucocorticoid administration exerts suppressive central effects on the anterior pituitary gland, leading to decreases in serum $\text{TSH}$.

  • Differentiated from primary hyperthyroidism because free $\text{T}_4$ and free $\text{T}_3$ levels are low or normal, rather than elevated.

• Biotin Therapy (Laboratory Artifact):

  • Ingestion of supplemental biotin (vitamin $\text{B}_7$) interferes with streptavidin-biotin immunoassays used in clinical laboratory testing.

  • Yields spurious results mimicking severe primary thyrotoxicosis: falsely low $\text{TSH}$ paired with falsely elevated free $\text{T}_4$, free $\text{T}_3$, and TSH receptor-binding inhibitor immunoglobulin ($\text{TBII}$).

Diagnostic Evaluation of Hyperthyroidism

• Hormonal Profiles and Disease Staging:

  • Primary Overt Hyperthyroidism: Defined biochemically by elevated serum free $\text{T}_4$ ($\uparrow\text{free T}_4$) and/or free $\text{T}_3$ alongside suppressed serum $\text{TSH}$ ($\downarrow\text{TSH}$).

  • Subclinical Hyperthyroidism: Defined by normal circulating free $\text{T}_4$ and free $\text{T}_3$ in the presence of suppressed serum $\text{TSH}$ ($\downarrow\text{TSH}$).

  • Secondary Hyperthyroidism: An exceptionally rare clinical entity caused by central pathology (such as a TSH-secreting pituitary adenoma), characterized by elevated free $\text{T}_4$ ($\uparrow\text{free T}_4$) accompanied by inappropriately elevated or normal serum $\text{TSH}$ ($\uparrow\text{TSH}$).

• Hypothalamic-Pituitary-Thyroid (HPT) Axis Feedback Physiology:

  • The hypothalamus synthesizes and releases thyrotropin-releasing hormone ($\text{TRH}$).

  • $\text{TRH}$ acts positively ($+$) on the anterior pituitary gland to stimulate the synthesis and secretion of $\text{TSH}$.

  • $\text{TSH}$ acts positively ($+$) on the thyroid gland to induce synthesis of thyroxine ($\text{T}_4$) and triiodothyronine ($\text{T}_3$).

  • Peripheral tissues convert prohormone $\text{T}_4$ to active hormone $\text{T}_3$.

  • Circulating $\text{T}_4$ and $\text{T}_3$ exert negative feedback inhibition ($-$) centrally on both the pituitary gland (suppressing $\text{TSH}$ release) and the hypothalamus (suppressing $\text{TRH}$ release).

• Thyroid Radioactive Iodine Uptake (RAIU) and Scintigraphy Scan:

  • Indicated in the diagnostic evaluation of confirmed hyperthyroidism with elevated free $\text{T}_4$.

  • Contraindications: Absolutely contraindicated during pregnancy and breastfeeding. While the diagnostic radiation dose is safe for adult tissues, radioactive isotopes readily cross the placenta and concentrate in breast milk, presenting severe risks of thyroid ablation to the fetus or nursing child.

  • Scintigraphy Findings: Graves disease displays a diffusely high, homogeneous isotope uptake throughout both lobes of the thyroid gland, differentiating it from low-uptake thyroiditis or patchy, autonomous toxic nodular diseases.

• Additional Diagnostic Modalities for Graves Disease:

  • Indicated when clinical history, physical examination, and initial radioactive uptake studies do not provide a definitive diagnosis.

  • Serologic Thyroid-Stimulating Autoantibodies:

  • Thyroid-stimulating immunoglobulin ($\text{TSI}$): Bioassay measuring antibody-mediated stimulation of receptor activity.

  • Thyroid receptor antibody ($\text{TRAb}$): Immunoassay assessing total binding competition at the receptor.

  • Color Doppler Ultrasound:

  • Assesses thyroid parenchymal vascular flow.

  • Hyperthyroid states exhibit markedly increased vascular flow (termed a "thyroid inferno"), reflecting intense metabolic and synthetic activity.

Management and Therapeutic Interventions for Graves Disease

• Medical (Pharmacologic) Management:

  • Mechanism: Antithyroid drugs (thionamides) actively inhibit the synthesis of new thyroid hormones.

  • Methimazole:

  • First-line pharmacologic agent for the majority of non-pregnant patients.

  • Teratogenicity: Methimazole is teratogenic (associated with aplasia cutis and choanal atresia) and must be avoided during pregnancy, particularly throughout the first trimester.

  • Laboratory Safety Monitoring: Requires ongoing surveillance of liver function tests (LFTs) due to the risk of drug-induced hepatotoxicity, as well as complete blood counts (CBC) to screen for rare but life-threatening agranulocytosis.

  • Propylthiouracil (PTU):

  • Agent of choice in pregnant patients during the first trimester, given its lower risk of major teratogenic malformations relative to methimazole.

  • Beta-Adrenergic Antagonists (Beta Blockers):

  • Provide symptomatic relief against tremor, palpitations, anxiety, and tachycardia by blunting sympathetic hyperactivation.

  • Do not inhibit thyroid hormone synthesis or alter the underlying autoimmune pathophysiology.

• Surgical Management (Thyroidectomy):

  • Benefits: Provides definitive, rapid treatment with a guaranteed cure of hyperthyroidism.

  • Risks & Trade-offs: Results in guaranteed permanent hypothyroidism, requiring lifelong exogenous thyroid hormone replacement therapy; carries inherent surgical and anesthetic risks (e.g., recurrent laryngeal nerve damage, accidental devascularization or resection of parathyroid glands causing hypocalcemia).

• Radioactive Iodine (RAI) Ablation:

  • Benefits: Destroys functional follicular thyroid tissue via beta-emission, preventing the ongoing need for chronic thionamide therapy.

  • Risks & Trade-offs: Involves a slightly increased lifetime risk of developing secondary malignancies; does not guarantee recovery of normal euthyroid function and frequently induces permanent hypothyroidism.

• Clinical Decision-Making Across Treatment Modalities:

  • Surgical intervention may be declined by patients who are poor operative candidates or who cannot travel to specialized surgical centers.

  • Radioactive iodine ablation requires home isolation protocols, making it suboptimal for patients who cannot maintain physical separation from young children or pregnant family members.

  • Management of Subclinical Disease: Active therapeutic intervention is frequently omitted in asymptomatic, healthy patients presenting with subclinical hyperthyroidism (normal free $\text{T}_4$ with low $\text{TSH}$).

• Post-Treatment Follow-up and Surveillance Protocols:

  • Early follow-up relies primarily on serial measurement of serum free $\text{T}_4$, because pituitary $\text{TSH}$ production can remain centrally suppressed for weeks to months following the restoration of euthyroidism.

  • Methimazole Protocol: Monitor free $\text{T}_4$ every $4\text{ to }6\text{ weeks}$ until biochemical stabilization and a steady maintenance dose are reached.

  • Remission in Graves Disease: Graves disease can undergo spontaneous clinical remission. If a patient on a stable, previously tolerated dose of methimazole develops biochemical hypothyroidism (elevated $\text{TSH}$, low free $\text{T}_4$), assess for disease remission and repeat $\text{TSI}$ testing. If high doses of thionamides fail to induce remission or sustain control, transition the patient toward radioactive iodine ablation or surgical thyroidectomy.

  • Radioactive Ablation Follow-up: Assess thyroid panel (free $\text{T}_4$ and $\text{TSH}$) every $4\text{ to }6\text{ weeks}$ until thyroid tissue is ablated, the patient becomes hypothyroid, and a therapeutic maintenance dose of levothyroxine is reached.

  • Surgical Follow-up: Assess free $\text{T}_4$ at discharge, evaluate $\text{TSH}$ at $6\text{ to }8\text{ weeks}$ postoperatively, and titrate daily levothyroxine dosing accordingly.

  • Patient Education: Hyperthyroidism is a manageable, chronic condition that requires dedicated lifelong monitoring to sustain euthyroid levels and prevent cardiovascular or skeletal complications.

Classification and Pathophysiology of Thyroiditis

• Overview of Thyroiditis:

  • An umbrella term covering a heterogeneous group of disorders united by inflammatory injury to the thyroid gland.

• Broad Clinical Categories:

  • Painful Thyroiditis:

  • Subacute granulomatous thyroiditis (de Quervain thyroiditis).

  • Acute suppurative thyroiditis (bacterial infection).

  • Radiation-induced thyroiditis.

  • Painless Thyroiditis:

  • Hashimoto thyroiditis (chronic autoimmune, presenting primarily with hypothyroidism).

  • Postpartum thyroiditis.

  • Subacute lymphocytic thyroiditis (sporadic autoimmune variant of Hashimoto).

  • Drug-induced thyroiditis.

• Distinct Forms of Thyroiditis:

  • Hashimoto Thyroiditis:

  • Clinical Presentation: Primary hypothyroidism.

  • Disease Course: Permanent destruction of thyroid parenchyma requiring lifelong hormone replacement.

  • Postpartum Thyroiditis:

  • Clinical Presentation: Initial hyperthyroidism followed by a hypothyroid phase.

  • Diagnostic Requirement & Course: Must occur specifically following childbirth; typically resolves spontaneously within $12\text{ to }18\text{ months}$.

  • Painless Thyroiditis (Subacute Lymphocytic):

  • Clinical Presentation: Initial hyperthyroidism followed by transient hypothyroidism.

  • Diagnostic Requirement & Course: Clinically identical to postpartum thyroiditis but must occur outside the postpartum window; typically self-resolves within $12\text{ to }18\text{ months}$.

  • Drug-Induced Thyroiditis:

  • Clinical Presentation: Can manifest variable presentations of hyperthyroidism or hypothyroidism.

  • Disease Course: Typically resolves following cessation of the causative pharmaceutical agent.

  • Infectious Thyroiditis (Subacute Granulomatous & Acute Suppurative):

  • Clinical Presentation: Exquisitely painful, tender thyroid gland accompanied by a systemic prodrome of fever, myalgias, and fatigue.

  • Subacute Course: Follows a distinct triphasic course—transient hyperthyroidism lasting $3\text{ to }6\text{ weeks}$, followed by subacute hypothyroidism lasting up to $6\text{ months}$, with complete normalization to euthyroid status achieved by $6\text{ to }12\text{ months}$.

Clinical Presentation and Physical Examination of Thyroiditis

• Symptom Profiles by Etiology:

  • Subacute and Acute Infectious Thyroiditis:

  • Often develops following a preceding viral upper respiratory illness (subacute) or bacterial seeding (acute).

  • Localized anterior neck tenderness, high fever, progressive dysphagia (difficulty swallowing), and dysphonia (hoarseness).

  • Acute Suppurative Thyroiditis:

  • Presents with severe focal anterior neck pain, an exquisitely tender and fluctuant thyroid, overlying cutaneous erythema, warmth, and systemic sepsis.

  • Hashimoto Thyroiditis:

  • Classical symptoms of hypometabolism: persistent fatigue, severe cold intolerance, generalized weight gain, constipation, dry skin, and lethargy.

  • Postpartum Thyroiditis:

  • Can manifest early adrenergic thyrotoxic symptoms (palpitations, irritability) or late hypothyroid symptoms (fatigue, postpartum depression, inability to shed gestational weight).

• Distinguishing Subacute Thyroiditis from Graves Disease on Physical Examination:

  • Subacute Thyroiditis:

  • Exquisitely tender to manual palpation over the thyroid gland.

  • Exhibits a shorter, self-limited disease duration.

  • Absence of extrathyroidal autoimmune manifestations.

  • Graves Disease:

  • Painless, non-tender, symmetrically enlarged diffuse goiter.

  • Extrathyroidal autoimmune signs: Exophthalmos (proptosis) and pretibial myxedema.

  • Auscultation may reveal a thyroid vascular bruit over the glandular lobes.

  • Characterized by a chronic, long-standing disease course.

Diagnostic Studies and Differential Diagnosis for Thyroiditis

• Laboratory and Diagnostic Profiles by Condition:

  • Subacute Thyroiditis:

  • Markedly elevated erythrocyte sedimentation rate ($\uparrow\text{ESR}$) and elevated C-reactive protein ($\text{CRP}$).

  • Normocytic, normochromic anemia and leukocytosis.

  • Thyroid autoantibodies are uniformly negative.

  • Acute Suppurative Thyroiditis:

  • Markedly elevated inflammatory markers ($\uparrow\text{ESR}$).

  • Severe peripheral leukocytosis accompanied by a prominent left shift (bandemia).

  • Diagnostic fine-needle aspiration ($\text{FNA}$) with Gram stain and microbiological culture to identify the causative bacterial pathogen.

  • Hashimoto Thyroiditis:

  • High circulating titers of thyroid autoantibodies: anti-thyroid peroxidase ($\text{anti-TPO}$) and anti-thyroglobulin ($\text{anti-Tg}$).

  • Subacute Lymphocytic Thyroiditis:

  • Positive thyroid autoantibodies ($\text{anti-TPO}$, $\text{anti-Tg}$) combined with a moderately elevated $\text{ESR}$.

  • Postpartum Thyroiditis:

  • Strongly positive thyroid autoantibodies ($\text{anti-TPO}$, $\text{anti-Tg}$).

• Differential Diagnosis for Thyroiditis:

  • Thyroid Lymphoma:

  • Primary thyroid B-cell non-Hodgkin lymphoma.

  • Occurs as a long-term complication in patients with chronic autoimmune Hashimoto thyroiditis.

  • Presents clinically as a rapidly enlarging, firm neck mass producing compressive symptoms.

  • Graves Disease:

  • Primary autoimmune hyperthyroidism presenting with thyrotoxicosis and diffuse goiter, distinguished by non-tender palpation, positive $\text{TSI}$ antibodies, and high radioactive iodine uptake.

Management, Follow-up, and Patient Education for Thyroiditis

• Etiology-Specific Treatment Protocols:

  • Subacute Granulomatous Thyroiditis:

  • High-dose nonsteroidal anti-inflammatory drugs (NSAIDs) for analgesia and control of glandular inflammation.

  • Initiate oral corticosteroids (e.g., prednisone) if neck pain fails to improve within $1\text{ week}$ of NSAID therapy.

  • Acute Suppurative Thyroiditis:

  • Intravenous or targeted oral antibiotic therapy.

  • May require percutaneous aspiration or surgical incision and drainage if abscess formation occurs.

  • Radiation-Induced Thyroiditis:

  • NSAIDs for localized neck discomfort; short courses of oral prednisone are rarely required for refractory inflammation.

  • Beta blockers to manage transient hyperthyroid adrenergic symptoms.

  • Hashimoto Thyroiditis:

  • Lifelong thyroid hormone replacement therapy using synthetic levothyroxine, titrated to normalize serum $\text{TSH}$.

  • Postpartum and Subacute Lymphocytic Thyroiditis:

  • Beta blockers during the initial, transient hyperthyroid phase.

  • Temporary levothyroxine replacement therapy during the subsequent hypothyroid phase if patients are symptomatic, with subsequent tapering to assess for endogenous glandular recovery.

  • Drug-Induced Thyroiditis:

  • Immediate discontinuation of the causative medication when clinically feasible.

  • Symptom-driven management with beta blockers (for hyperthyroid phases) or temporary levothyroxine (for persistent hypothyroid dysfunction).

• Patient Education and Long-Term Prognosis:

  • Approximately $50\%$ of women diagnosed with postpartum thyroiditis will develop permanent, irreversible primary hypothyroidism within $9\text{ years}$ of the initial diagnosis.

  • Preemptively counsel and establish baseline thyroid function testing in patients initiating pharmacological agents known to cause drug-induced thyroiditis (e.g., amiodarone, lithium, interferon-alpha, and immune checkpoint inhibitors).

  • Routine follow-up evaluation and serial surveillance are necessary to detect delayed progression into permanent primary hypothyroidism.

Questions & Discussion

• Question: Why can thyroiditis present initially as hyperthyroidism and subsequently transition into hypothyroidism?

• Pathophysiologic Explanation:

  • Hyperthyroid Phase (Thyrotoxic Leakage):

  • The initial inflammatory assault (whether viral, autoimmune, or drug-induced) damages thyroid follicular cell membranes.

  • This structural disruption leads to an unregulated leakage of preformed, stored thyroxine ($\text{T}_4$) and triiodothyronine ($\text{T}_3$) from damaged colloid stores directly into the capillary circulation.

  • This massive release produces a transient clinical state of thyrotoxicosis/hyperthyroidism lasting approximately $3\text{ to }6\text{ weeks}$.

  • Radioactive iodine uptake is low during this phase because the damaged follicular cells cannot actively transport iodine, and endogenous $\text{TSH}$ is centrally suppressed.

  • Hypothyroid Phase (Follicular Depletion):

  • Because the follicular epithelium is inflamed and structural integrity is compromised, the enzymatic synthesis of new thyroid hormone is halted.

  • Once the preformed, leaked circulating hormones are cleared by peripheral metabolism, the thyroid becomes depleted of hormone reserves.

  • This depletion precipitates an acute hypothyroid phase, which typically persists for up to $6\text{ months}$.

  • Recovery or Permanent Failure (Resolution):

  • As glandular inflammation resolves, the follicular epithelium regenerates, normal cellular architecture is restored, and the gland resumes endogenous synthesis of $\text{T}_4$ and $\text{T}_3$.

  • In most subacute cases, patients return to an asymptomatic, euthyroid state within $6\text{ to }12\text{ months}$.

  • However, in conditions with chronic or extensive parenchymal destruction (such as Hashimoto thyroiditis or a subset of postpartum thyroiditis cases), follicular regeneration fails, resulting in permanent hypothyroidism.